United Kingdom · Question · Written question
UIN 176003
Idiopathic Pulmonary Fibrosis: Nintedanib and Pirfenidone
Original
Introduced
25 March 2021
Last action
13 April 2021 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
13 April 2021
Summary
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of providing universal access to Pirfenidone and Nintedanib for people with Idiopathic Pulmonary Fibrosis.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
25 March 2021
Written question
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of providing universal access to Pirfenidone and Nintedanib for people with Idiopathic Pulmonary Fibrosis.
Source: Commons
13 April 2021
Answer
The National Institute for Health and Care Excellence (NICE) is the independent body responsible for producing evidence-based guidance for the National Health Service on whether medicines represent a clinically and cost-effective use of resources. NICE ha...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2021-03-25/176003
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1306232
- uk · wq-1306232 · source updated 13 April 2021